Press Release: GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

Saved in:
Bibliographic Details
Published inDow Jones Institutional News
Format Newsletter
LanguageEnglish
Published New York Dow Jones & Company Inc 01.03.2023
Subjects
Clinical trials
Contrast agents
Innovations
Magnetic resonance imaging
Patients
Pharmaceuticals
Trace elements
Ultrasonic imaging
Online AccessGet full text

Cover

More Information
Description not available.